MECHANIZMY PROWADZĄCE DO ANGIOGEGNEZY  W NOWOTWORACH

Magdalena Tchorzewska; Malwina Kowalik; Adrianna Kuliś; Wioletta Olejarz

doi:10.56782/pps.20

Published : 2019-08-07

Vol. 17 No. 10 (2019)

MECHANISMS LEADING TO ANGIOGEGNESIS IN CANCERS

Magdalena Tchorzewska

Malwina Kowalik

Adrianna Kuliś

Wioletta Olejarz

DOI: https://doi.org/10.56782/pps.20

Abstract

Angiogenesis is a multi-stage process which involves the formation of capillaries from the preexisting vasculature. There can be distinguished a number of functions and substances that stimulate and inhibit this process, known as an angiogenesis stimulator or inhibitor. Vascular endothelial growth factor (VEGF), are the main chemical signals that induce blood formation. Among many angiogenesis inhibitors, angiostatin, endostatin and thrombospondin play an important role. It is very important to keep a balance between activators and inhibitors. Large amount of angiogenesis stimulator may cause progression to malignant cancer. Tumor angiogenesis allows for supply of oxygen, nutrients, growth factors, and tumor dissemination to distant sites. Inhibition of angiogenesis appears to be an important prognostic factor in the treatment of cancer.

Keywords:

angiogenesis, VEGF, angiopoietin, cancer, anti-angiogenic therapy

Most read articles by the same author(s)

Aleksandra Grzybowska, Tomasz Lorenc, Wioletta Olejarz, Grażyna Nowicka, EXOSOMES AS CARRIERS OF INFORMATION BEETWEN TUMOR CELLS , Prospects in Pharmaceutical Sciences: Vol. 17 No. 2 (2019)
Mateusz Żaczko, Tomasz Lorenc, Wioletta Olejarz, Grażyna Nowicka, PERSPECTIVES OF THERAPEUTIC USE OF EXOSOMES IN THE MOST COMMON CANCERS , Prospects in Pharmaceutical Sciences: Vol. 17 No. 6 (2019)
Dominika Łacheta, Wioletta Olejarz, OCHRONNA ROLA KWASU α-LIPONOWEGO W MIAŻDŻYCY I CHOROBACH SERCOWO-NACZYNIOWYCH , Prospects in Pharmaceutical Sciences: Vol. 17 No. 8 (2019)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Tchorzewska, M., Kowalik, M., Kuliś, A., & Olejarz, W. (2019). MECHANISMS LEADING TO ANGIOGEGNESIS IN CANCERS. Prospects in Pharmaceutical Sciences, 17(10), 60–65. https://doi.org/10.56782/pps.20

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003, 9(6), 653-660. DOI: https://doi.org/10.1038/nm0603-653

Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012, 320(2), 130-137. DOI: https://doi.org/10.1016/j.canlet.2012.03.008

Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017, 5(2). DOI: https://doi.org/10.3390/biomedicines5020034

Szala S, Jarosz M. [Tumor blood vessels]. Postepy Hig Med Dosw(Online). 2011, 65, 437-446. DOI: https://doi.org/10.5604/17322693.951193

Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002, 29(6 Suppl 16), 15-18. DOI: https://doi.org/10.1053/sonc.2002.37263

Sivridis E, Giatromanolaki A, Koukourakis MI. The vascular network of tumours--what is it not for? J Pathol. 2003, 201(2), 173-180. DOI: https://doi.org/10.1002/path.1355

Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008, 66(1), 1-9. DOI: https://doi.org/10.1016/j.critrevonc.2007.07.004

Szala S. [Angiogenesis and immune suppression: yin and yang of tumor progression?]. Postepy Hig Med Dosw (Online). 2009, 63, 598-612.

Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009, 19(5), 329-337. DOI: https://doi.org/10.1016/j.semcancer.2009.05.003

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002, 420(6917), 860-867. DOI: https://doi.org/10.1038/nature01322

Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010, 10(4), 369-373. DOI: https://doi.org/10.2174/156652410791316968

Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006, 16(1), 3-15. DOI: https://doi.org/10.1016/j.semcancer.2005.07.008

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23(11), 549-555. DOI: https://doi.org/10.1016/S1471-4906(02)02302-5

Jarosz-Biej M, Kaminska N, Matuszczak S, Cichon T, Pamula-Pilat J, Czapla J, Smolarczyk R, Skwarzynska D, Kulik K, Szala S. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma. PLoS One. 2018, 13(1), e0191012. DOI: https://doi.org/10.1371/journal.pone.0191012

Kobayashi SD, Voyich JM, Burlak C, DeLeo FR. Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz). 2005, 53(6), 505-517.

Liang W, Ferrara N. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis. Cancer Immunol Res. 2016, 4(2), 83-91. DOI: https://doi.org/10.1158/2326-6066.CIR-15-0313

Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front Physiol. 2018, 9, 113. DOI: https://doi.org/10.3389/fphys.2018.00113

Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol. 2009, 90(3), 222-231. DOI: https://doi.org/10.1111/j.1365-2613.2009.00641.x

Roy R, Morad G, Jedinak A, Moses MA. Metalloproteinases and their roles in human cancer. Anat Rec (Hoboken). 2019. DOI: https://doi.org/10.1002/ar.24188

Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019, 68(5), 823-833. DOI: https://doi.org/10.1007/s00262-018-2255-4

Xing Y, Tian Y, Kurosawa T, Matsui S, Touma M, Yanai T, Wu Q, Sugimoto K. CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis. Genes Cells. 2016, 21(6), 624-638. DOI: https://doi.org/10.1111/gtc.12371

Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008, 8(8), 618-631. DOI: https://doi.org/10.1038/nrc2444

Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers. F1000Prime Rep. 2015, 7, 09. DOI: https://doi.org/10.12703/P7-09

Ribatti D, Tamma R, Vacca A. Mast Cells and Angiogenesis in Human Plasma Cell Malignancies. Int J Mol Sci. 2019, 20(3). DOI: https://doi.org/10.3390/ijms20030481

Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004, 10(9), 950-958. DOI: https://doi.org/10.1038/nm1097

Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017, 45, 43-51. DOI: https://doi.org/10.1016/j.coi.2017.01.002

Albini A, Bruno A, Noonan DM, Mortara L. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Front Immunol. 2018, 9, 527. DOI: https://doi.org/10.3389/fimmu.2018.00527

Bosisio D, Ronca R, Salvi V, Presta M, Sozzani S. Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. Curr Opin Immunol. 2018, 53, 180-186. DOI: https://doi.org/10.1016/j.coi.2018.05.011

Shen Z, Gu X, Mao W, Cao H, Zhang R, Zhou Y, Liu K, Wang L, Zhang Z, Yin L. Dendritic cells fused with endothelial progenitor cells play immunosuppressive effects on angiogenesis in acute myeloid leukemia mice. Am J Transl Res. 2019, 11(5), 2816-2829.

Mishra PJ, Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res. 2009, 69(4), 1255-1258. DOI: https://doi.org/10.1158/0008-5472.CAN-08-3562

Muerkoster SS, Werbing V, Koch D, Sipos B, Ammerpohl O, Kalthoff H, Tsao MS, Folsch UR, Schafer H. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases. Int J Cancer. 2008, 123(8), 1751-1760. DOI: https://doi.org/10.1002/ijc.23703

Schito L. Hypoxia-Dependent Angiogenesis and Lymphangiogenesis in Cancer. Adv Exp Med Biol. 2019, 1136, 71-85. DOI: https://doi.org/10.1007/978-3-030-12734-3_5

Al-Zoughbi W, Hoefler G. Tumor Macroenvironment: An Update. Pathobiology. 2019, 1-3. DOI: https://doi.org/10.1159/000502097

Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008, 358(19), 2039-2049. DOI: https://doi.org/10.1056/NEJMra0706596

Sacewicz I, Wiktorska M, Wysocki T, Niewiarowska J. [Mechanisms of cancer angiogenesis]. Postepy Hig Med Dosw (Online). 2009, 63, 159-168.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285(21), 1182-1186. DOI: https://doi.org/10.1056/NEJM197111182852108

Li H, Zhao B, Liu Y, Deng W, Zhang Y. Angiogenesis in residual cancer and roles of HIF-1alpha, VEGF, and MMP-9 in the development of residual cancer after radiofrequency ablation and surgical resection in rabbits with liver cancer. Folia Morphol (Warsz). 2019.

Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013, 328(1), 18-26. DOI: https://doi.org/10.1016/j.canlet.2012.08.018

Kurzyk A. [Angiogenesis - possibilities, problems and perspectives]. Postepy Biochem. 2015, 61(1), 25-34.

Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006, 312(5777), 1171-1175. DOI: https://doi.org/10.1126/science.1125950

Szala S, Mitrus I, Sochanik A. Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy? Cancer Immunol Immunother. 2010, 59(10), 1449-1455. DOI: https://doi.org/10.1007/s00262-010-0873-6

Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007, 13(13), 3951-3959. DOI: https://doi.org/10.1158/1078-0432.CCR-07-0374

Lin Z, Zhang Q, Luo W. Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. Eur J Pharmacol. 2016, 793, 76-81. DOI: https://doi.org/10.1016/j.ejphar.2016.10.039

Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006, 5(2), 147-159. DOI: https://doi.org/10.1038/nrd1957

Verheul HM, Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs. 2005, 10(2), 403-412. DOI: https://doi.org/10.1517/14728214.10.2.403

Booy EP, Johar D, Maddika S, Pirzada H, Sahib MM, Gehrke I, Loewen S, Louis SF, Kadkhoda K, Mowat M, Los M. Monoclonal and bispecific antibodies as novel therapeutics. Arch Immunol Ther Exp (Warsz). 2006, 54(2), 85-101. DOI: https://doi.org/10.1007/s00005-006-0011-5

Jaszai J, Schmidt MHH. Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells. 2019, 8(9). DOI: https://doi.org/10.3390/cells8091102

Antoniak K, Nowak JZ. [Bevacizumab: progress in the treatment of metastatic cancer and hope for patients with proliferative retinopathy]. Postepy Hig Med Dosw (Online). 2007, 61, 320-330.

Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S, Roccaro AM. Exosomes in Tumor Angiogenesis. Methods Mol Biol. 2016, 1464, 25-34. DOI: https://doi.org/10.1007/978-1-4939-3999-2_3

Szala S, Szary J, Cichon T, Sochanik A. Antiangiogenic gene therapy in inhibition of metastasis. Acta Biochim Pol. 2002, 49(2), 313-321. DOI: https://doi.org/10.18388/abp.2002_3789

Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol. 2016, 27 Suppl 1, i33-i39. DOI: https://doi.org/10.1093/annonc/mdw093

Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med. 2017, 7(7). DOI: https://doi.org/10.1101/cshperspect.a026781

Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017, 20(2), 185-204. DOI: https://doi.org/10.1007/s10456-017-9552-y

Magdalena Tchorzewska

Affiliation:

Zakład Biochemii i Farmakogenomiki, Warszawski Uniwersytet Medyczny, Banacha 1, 02-097 Warszawa; Centrum Badań Przedklinicznych Warszawskiego Uniwersytetu Medycznego, Banacha 1b, 02-097 Warszawa Poland

Malwina Kowalik

Affiliation:

Adrianna Kuliś

Affiliation:

Zakład Biochemii i Farmakogenomiki, Warszawski Uniwersytet Medyczny,Banacha 1, 02-097 Warszawa; Centrum Badań Przedklinicznych Warszawskiego Uniwersytetu Medycznego, Banacha 1b, 02-097 Warszawa Poland

Wioletta Olejarz

wioletta.olejarz@wum.edu.pl